ly 2780301

LY2780301 is an orally bioavailable inhibitor of the serine threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

ORM-13070 is a selective antagonist radioligand for the α2C adrenoceptor subtype. ORM-13070 C-11 is under investigation in clinical trial.